HK3293A - Dihydropyridine derivatives, their production and use - Google Patents

Dihydropyridine derivatives, their production and use

Info

Publication number
HK3293A
HK3293A HK32/93A HK3293A HK3293A HK 3293 A HK3293 A HK 3293A HK 32/93 A HK32/93 A HK 32/93A HK 3293 A HK3293 A HK 3293A HK 3293 A HK3293 A HK 3293A
Authority
HK
Hong Kong
Prior art keywords
dihydropyridine
alkyl
piperazinyl
cycloalkyl
ethyl
Prior art date
Application number
HK32/93A
Other languages
English (en)
French (fr)
Inventor
Kanji Meguro
Akinobu Nagaoka
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP1982/000159 external-priority patent/WO1983004023A1/ja
Priority claimed from PCT/JP1983/000008 external-priority patent/WO1984002702A1/ja
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Publication of HK3293A publication Critical patent/HK3293A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)

Claims (21)

1. Dihydropyridin-Derivat der Formel (I) (in der R1, R2 und R3 gleich oder verschieden sind und jeweils C1-6-Alkyl, C3-6-Cycloalkyl-C1-6-alkyl, C3-6-Cycloalkyl oder C3-7-Alkoxyalkyl sind; R4 und R5 gleich oder verschieden sind und jeweils Wasserstoff, Halogen, Nitro, Trifluoromethyl, C1-6-Alkyl, C3-6-Cycloalkyl-C1-6-alkyl, C3-6-Cycloalkyl, C1-3-Alkoxy, Cyano, C2-4-Alkoxycarbonyl oder C1-3-Alkylthio sind; R6 Wasserstoff, C1-6-Alkyl, C3-6-Cycloalkyl-C1-6-alkyl, C3-6-Cycloalkyl, Phenyl-C1-3-alkyl, Phenyl oder Naphthyl, das die gleichen oder unterschiedliche Substituenten R4 und R5 in wahlweisen Positionen haben kann, oder Pyridyl ist; X Sauerstoff, Schwefel, Vinylen, Azomethin oder eine Gruppe der FormelA C2-4-Alkylen ist; Ar Phenyl oder Naphthyl oder ein Pyridyl ist; m eine ganze Zahl von 1 bis 3 ist; n eine ganze Zahl von 0 bis 2 ist) oder ein pharmazeutisch annehmbares Säureadditionssalz desselben.
2. Dihydropyridin-Derivat nach Anspruch 1, worin m 2 ist.
3. Dihydropyridin-Derivat nach Anspruch 1, worin A Ethylen ist.
4. Dihydropyridin-Derivat nach Anspruch 1, worin X Vinylen ist.
5. Dihydropyridin-Derivat nach Anspruch 1, worin X Azo methin ist.
6. Dihydropyridin-Derivat nach Anspruch 1, worin X Sauerstoff ist.
7. Dihydropyridin-Derivat nach Anspruch 1, worin Ar Phenyl ist.
8. Dihydropyridin-Derivat nach Anspruch 1, worin R6 und Ar jeweils eine Phenyl-Gruppe sind, die gegebenenfalls substituiert sein kann, und n 1 ist.
9. Dihydropyridin-Derivat nach Anspruch 1, worin Ar eine Phenyl-Gruppe ist, die gegebenenfalls substituiert sein kann, X Vinylen ist, A Ethylen ist, m 2 ist und n 0 ist.
10. Dihydropyridin-Derivat nach Anspruch 1, worin R6 und Ar jeweils Phenyl ist, X Vinylen ist, A Ethylen ist, m 2 ist und n 1 ist.
11. Dihydropyridin-Derivat nach Anspruch 1, worin Ar eine Phenyl-Gruppe ist, die gegebenenfalls durch ein oder zwei Halogen-Atome substituiert ist, X Vinylen ist, A Ethylen ist, m 2 ist und n 0 ist.
12. Dihydropyridin-Derivat nach Anspruch 1, worin Ar eine Phenyl-Gruppe ist, die gegebenenfalls durch ein oder zwei Chlor-Atome substituiert ist, X Vinylen ist, A Ethylen ist, m 2 ist und n 0 ist.
13. Dihydropyridin-Derivat nach Anspruch 1, das 2-(4-Benzhydryl-l-piperazinyl)ethyl-methyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridin-3.5-dicarboxylat ist.
14. Dihydropyridin-Derivat nach Anspruch 1, das 2-[4-(4,4'-Difluorobenzhydryl)-1-piperazinyl]ethyl- methyl-2,6-dimethyl-4-(3-nitrophenyl)-1.4-dihydropyridin-3,5-dicarboxylat ist.
15. Dihydropyridin-Derivat nach Anspruch 1, das 2-[4-(4,4'-Dimethylbenzhydryl)-1-piperazinyl]ethyl- methyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridin-3,5-dicarboxylat ist.
16. Dihydropyridin-Derivat nach Anspruch 1, das 2-[4-(4,4'-Dichlorobenzhydryl)-1-piperazinyl]ethyl- methyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridin-3,5-dicarboxylat ist.
17. Dihydropyridin-Derivat nach Anspruch 1, das 2-[4-(3-Chlorophenyl)-1-piperazinyl]ethyl-methyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridin-3,5-dicarboxylat ist.
18. Dihydropyridin-Derivat nach Anspruch 1, das 2-(4-Benzhydryl-1-piperazinyl)ethyl-methyl-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarboxylat ist.
19. Pharmazeutische Zusammensetzung, umfassend als Wirkstoff eine wirksame Menge eines Dihydropyridin-Derivats oder eines Salzes desselben nach einem der Ansprüche 1 bis 18 und ein pharmazeutisch annehmbares Trägermaterial oder Verdünnungsmittel dafür.
20. Verfahren zur Herstellung eines Dihydropyridin-Derivats der Formel (I) (in der R1, R2 und R3 gleich oder verschieden sind und jeweils C1-6-Alkyl, C3-6-Cycloalkyl-C1-6-alkyl, C3-6-Cycloalkyl oder C3-7-Alkoxyalkyl sind; R4 und R5 gleich oder verschieden sind und jeweils Wasserstoff, Halogen, Nitro, Trifluoromethyl, C1-6-Alkyl, C3-6-Cycloalkyl-C1-6-alkyl, C3-6-Cycloalkyl, C1-3-Alkoxy, Cyano, C2-4-Alkoxycarbonyl oder C1-3-Alkylthio sind; R6 Wasserstoff, C1-6-Alkyl, C3-6-Cycloalkyl-C1-6-alkyl, C3-6-Cycloalkyl, Phenyl-C1-3-alkyl, Phenyl oder Naphthyl, das die gleichen oder unterschiedliche Substituenten R4 und R5 in wahlweisen Positionen haben kann, oder Pyridyl ist; X Sauerstoff, Schwefel, Vinylen, Azomethin oder eine Gruppe der Formel A C2-4-Alkylen ist; Ar Phenyl oder Naphthyl oder ein Pyridyl ist; m eine ganze Zahl von 1 bis 3 ist; n eine ganze Zahl von 0 bis 2 ist) oder eines pharmazeutisch annehmbaren Säureadditionssalzes desselben, worin irgendeines der Fragmente, die das Derivat zu bilden vermögen, der Reaktion der Dehydrierung und Cyclisierung mit dem verbleibenden Fragment oder den verbleibenden Fragmenten nach einem der folgenden Herstellungsverfahren (A) bis (F) unterworfen wird: wobei in den vorstehenden Formeln (II) bis (VIII) die verschiedenen Symbole die gleichen Bedeutungen haben, wie sie in Verbindung mit der Formel (I) angegeben sind, und gegebenenfalls das Dihydropyridin-Derivat (I) durch Reaktion mit einer geeigneten Säure in an sich bekannter Weise in ein pharmazeutisch annehmbares Säureadditionssalz überführt wird.
21. Dihydropyridin-Derivate und deren pharmazeutisch annehmbare Salze zur Verwendung bei der Herstellung von Medikamenten als prophylaktische und/oder therapeutische Arzneimittel für Herz-Kreislauf-Erkrankungen, wobei die Dihydropyridin-Derivate die Formel (I) haben, (in der R1, R2 und R3 gleich oder verschieden sind und jeweils C1-6-Alkyl, C3-6-Cycloalkyl-C,_s-alkyl, C3-6-Cycloalkyl oder C3-7-Alkoxyalkyl sind; R4 und R5 gleich oder verschieden sind und jeweils Wasserstoff, Halogen, Nitro, Trifluoromethyl, C1-6-Alkyl, C3-6-Cycloalkyl-C1-8-alkyl, C3-6-Cycloalkyl, C1-3-Alkoxy, Cyano, C2-4-Alkoxycarbonyl oder C1-3-Alkylthio sind; R6 Wasserstoff, C1-6-Alkyl, C3-6-Cycloalkyl-C1-6-alkyl, C3-6-Cycloalkyl, Phenyl-C1-3-alkyl, Phenyl oder Naphthyl, das die gleichen oder unterschiedliche Substituenten R4 und R5 in wahlweisen Positionen haben kann, oder Pyridyl ist; X Sauerstoff, Schwefel, Vinylen, Azomethin oder eine Gruppe der Formel A C2-4-Alkylen ist; Ar Phenyl oder Naphthyl oder ein Pyridyl ist; m eine ganze Zahl von 1 bis 3 ist; n eine ganze Zahl von 0 bis 2 ist) und die Salze pharmazeutisch annehmbare Säureadditionssalze der Verbindungen (I) sind.
HK32/93A 1982-05-10 1993-01-14 Dihydropyridine derivatives, their production and use HK3293A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP1982/000159 WO1983004023A1 (en) 1982-05-10 1982-05-10 Dihydropyridine derivatives
PCT/JP1983/000008 WO1984002702A1 (fr) 1983-01-11 1983-01-11 Derives de dihydropyridine

Publications (1)

Publication Number Publication Date
HK3293A true HK3293A (en) 1993-01-21

Family

ID=26422991

Family Applications (1)

Application Number Title Priority Date Filing Date
HK32/93A HK3293A (en) 1982-05-10 1993-01-14 Dihydropyridine derivatives, their production and use

Country Status (16)

Country Link
US (1) US4892875A (de)
EP (1) EP0094159B1 (de)
KR (1) KR880002357B1 (de)
AT (1) ATE50987T1 (de)
AU (1) AU556150B2 (de)
CA (1) CA1333487C (de)
DK (1) DK160984C (de)
ES (3) ES8607966A1 (de)
FI (1) FI79700C (de)
GR (1) GR78252B (de)
HK (1) HK3293A (de)
IE (1) IE56057B1 (de)
IL (1) IL68494A (de)
MY (1) MY102082A (de)
NO (1) NO159593C (de)
PT (1) PT76653B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0097821B1 (de) * 1982-06-03 1988-07-13 Pierrel S.p.A. Dihydropyridine mit Calciumantagonistischer Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
WO1985000169A1 (fr) * 1983-06-21 1985-01-17 Sandoz Ag Derives de 1,4-dihydropyridine, leur fabrication et les preparations pharmaceutiques les contenant
JPS60120861A (ja) * 1983-12-02 1985-06-28 Otsuka Pharmaceut Co Ltd ジヒドロピリジン誘導体
US5137889A (en) * 1983-12-02 1992-08-11 Otsuka Pharmaceutical Co., Ltd. Dihydropyridine derivatives and process for preparing the same
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
IE57810B1 (en) * 1984-03-27 1993-04-21 Delagrange Lab 1,4-dihydropyridine derivatives,their preparation and their use
US4755512A (en) * 1984-04-11 1988-07-05 Bristol-Myers Company Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters incorporating arylpiperazinylalkyl moities
US4895846A (en) * 1984-04-11 1990-01-23 Bristol-Myers Company Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters incorporating arylpiperazinylalkyl moieties
FI853477L (fi) * 1984-09-14 1986-03-15 Ciba Geigy Ag Foerfarande foer framstaellning av karbonylfoereningar.
ATE107284T1 (de) * 1984-09-28 1994-07-15 Byk Gulden Lomberg Chem Fab Neue diarylverbindungen.
IT1196272B (it) * 1984-09-28 1988-11-16 Poli Ind Chimica Spa Derivati di 1,4-diidropiridina e composizioni farmaceutiche che li contengono
HUT39179A (en) * 1984-12-10 1986-08-28 Sandoz Ag Process for production of derivatives of 1,4-dihydro-piridin
WO1986003748A1 (fr) * 1984-12-21 1986-07-03 Byk Gulden Lomberg Chemische Fabrik Gesellschaft M Nouveaux derives de piperazine
IT1191845B (it) * 1986-01-20 1988-03-23 Dompe Farmaceutici Spa Alchiloli derivati farmacologicamente attivi
DK114587A (da) * 1986-03-12 1987-09-13 Byk Gulden Lomberg Chem Fab Monocycliske esterderivater
US4814455A (en) * 1986-04-16 1989-03-21 Bristol-Myers Company Dihydro-3,5-dicarboxylates
US4868181A (en) * 1986-08-04 1989-09-19 E. I. Du Pont De Nemours And Company 1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
JPH0725750B2 (ja) * 1987-12-18 1995-03-22 富士レビオ株式会社 １，４‐ジヒドロピリジン誘導体
ES2143453T3 (es) * 1988-05-19 2000-05-16 Yoshitomi Pharmaceutical Uso de derivados de dihidropiridina para la profilaxis o el tratamiento de trastornos de la circulacion cerebral.
US5286869A (en) * 1988-12-15 1994-02-15 Fujirebio Kabushiki Kaisha 1,4-dihydropyridine derivatives
JP2838282B2 (ja) * 1988-12-29 1998-12-16 吉富製薬株式会社 血管攣縮治療剤
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
ES2287110T3 (es) * 2000-04-11 2007-12-16 Sankyo Company, Limited Composicion farmaceutica estabilizada que contiene un bloqueador de calcio consistente en azelnidipina.
WO2002017913A1 (en) * 2000-08-30 2002-03-07 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
CA2495962A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
DE602005021641D1 (de) 2004-06-08 2010-07-15 Nsab, Filial Af Neurosearch Sweden Ab Neue disubstituierte phenylpiperidine und piperazine als modulatoren der dopamin-neurotransmission
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
JP2008501749A (ja) * 2004-06-08 2008-01-24 ニューロサーチ スウェーデン アクチボラゲット ドーパミン及びセロトニン神経伝達のモジュレーターとしての新規なジ置換フェニルピペリジン
MX2007000979A (es) * 2004-07-26 2007-07-11 Cotherix Inc Tratamiento de la hipertension pulmonar por iloprost inhalado con una formulacion microparticulada.
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP1951253A2 (de) 2005-10-26 2008-08-06 Cotherix, Inc. Fasudil in kombinationstherapien zur behandlung von pulmonaler arterieller hypertonie
EP2351569B1 (de) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Kombinationstherapie mit Fasudil zur Behandlung von pulmonaler Hypertonie
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
CN101215258A (zh) * 2008-01-21 2008-07-09 中国药科大学 二氢吡啶类钙拮抗剂化合物及其制备方法与医药用途
CN101575313B (zh) * 2009-01-20 2012-04-18 许昌恒生制药有限公司 无柱层析法分离合成盐酸马尼地平生产工艺
WO2011023954A2 (en) * 2009-08-27 2011-03-03 Cipla Limited Polymorphic forms of manidipine
US8883844B2 (en) 2010-09-24 2014-11-11 Nitrogenix Inc. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
HK1206297A1 (en) 2012-04-04 2016-01-08 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
CN102875451B (zh) * 2012-04-05 2014-12-03 常州制药厂有限公司 一种盐酸马尼地平合成工艺的改进方法
MX2015014666A (es) 2013-04-17 2016-03-01 Pfizer Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
CN103351362A (zh) * 2013-06-17 2013-10-16 张家港威胜生物医药有限公司 一种马尼地平中间体2-(4-二苯甲基哌嗪)乙基乙酰乙酸酯的制备方法
CN103467364B (zh) * 2013-06-21 2015-07-15 四川海思科制药有限公司 一种盐酸马尼地平化合物
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN106518806A (zh) * 2016-09-07 2017-03-22 张家港威胜生物医药有限公司 一种马尼地平中间体2‑(4‑二苯甲基哌嗪)乙基乙酰乙酸酯的制备方法
CN106380442A (zh) * 2016-09-07 2017-02-08 张家港威胜生物医药有限公司 一种钙离子通道拮抗剂马尼地平的制备方法
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472853A (en) * 1967-05-29 1969-10-14 Sterling Drug Inc 1-((pyrido(2,1-c)-s-triazolyl)-lower-alkyl)-4-substituted- piperazines
DE2218644C3 (de) * 1972-04-18 1982-08-19 Bayer Ag, 5090 Leverkusen Basische Ester von 1,4-Dihydropyridinen, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE2239815C2 (de) * 1972-08-12 1983-02-10 Bayer Ag, 5090 Leverkusen 2-Alkylamino-dihydropyridine, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
GB1455502A (en) * 1973-02-20 1976-11-10 Yamanouchi Pharma Co Ltd 1,4-dihydropyridine derivatives
JPS55301A (en) * 1978-02-14 1980-01-05 Yamanouchi Pharmaceut Co Ltd 1,4-dihydropyridine-3,5-dicarboxylic ester derivative and its preparation
DE2949464A1 (de) * 1978-12-18 1980-06-26 Sandoz Ag Benzoxadiazole und benzothiadiazole, ihre herstellung und verwendung
DE3022030A1 (de) * 1980-06-12 1981-12-17 Bayer Ag, 5090 Leverkusen 4-thiazol- bzw. 4-imidazol-substituierte, 1,4-dihydropyridine, verfahren zu deren herstellung sowie diese enthaltende arzneimittel
DE3042769A1 (de) * 1980-11-13 1982-06-09 Bayer Ag, 5090 Leverkusen C-3 verknuepfte 1,4-dihydropyridine, ihre verwendung in arzneimitteln und verfahren zu ihrer herstellung
CS228917B2 (en) * 1981-03-14 1984-05-14 Pfizer Method of preparing substituted derivatives of 1,4-dihydropyridine
JPS57175166A (en) * 1981-04-23 1982-10-28 Banyu Pharmaceut Co Ltd Carbamoyloxyalkyl-1,4-dihydropyridine derivative and its preparation
DE3269219D1 (en) * 1981-11-17 1986-03-27 Fisons Plc Dihydropyridines, methods for their production and their formulation and use as pharmaceuticals

Also Published As

Publication number Publication date
DK203083D0 (da) 1983-05-06
IE56057B1 (en) 1991-04-10
KR840004741A (ko) 1984-10-24
IL68494A0 (en) 1983-07-31
FI831604A0 (fi) 1983-05-09
ES8701171A1 (es) 1986-11-16
IE830897L (en) 1983-11-10
FI831604L (fi) 1983-11-11
ES547275A0 (es) 1986-11-16
DK160984B (da) 1991-05-13
NO831613L (no) 1983-11-11
IL68494A (en) 1988-01-31
NO159593B (no) 1988-10-10
US4892875A (en) 1990-01-09
PT76653A (en) 1983-06-01
EP0094159B1 (de) 1990-03-14
KR880002357B1 (ko) 1988-10-29
AU1415583A (en) 1983-11-17
AU556150B2 (en) 1986-10-23
CA1333487C (en) 1994-12-13
MY102082A (en) 1992-03-31
ATE50987T1 (de) 1990-03-15
NO159593C (no) 1989-01-18
DK160984C (da) 1991-11-11
PT76653B (en) 1986-01-27
GR78252B (de) 1984-09-26
ES8602661A1 (es) 1985-12-01
ES8607966A1 (es) 1986-01-16
DK203083A (da) 1983-11-11
FI79700C (fi) 1990-02-12
FI79700B (fi) 1989-10-31
EP0094159A1 (de) 1983-11-16
ES522199A0 (es) 1986-01-16
ES541668A0 (es) 1985-12-01

Similar Documents

Publication Publication Date Title
EP0094159B1 (de) Dihydropyridinderivate, deren Herstellung und Verwendung
US4220649A (en) 1,4-Dihydropyridine-3,5-dicarboxylic acid ester derivatives
US4999362A (en) 2-thiomethyl-substituted-1,4-dihydropyridines, method for their preparation and pharmaceutical compositions containing them
EP0176956B1 (de) Neue Diarylverbindungen
US4755512A (en) Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters incorporating arylpiperazinylalkyl moities
EP0138505A2 (de) Dihydropyridin-Derivate, ihre Herstellung und Verwendung
CZ281597B6 (cs) Enantiomery 1,4-dihydropyridinu, způsob jejich přípravy a farmaceutické prostředky z nich připravené
EP0097821A2 (de) Dihydropyridine mit Calciumantagonistischer Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
EP0197488A2 (de) 1,4-Dihydropyridinderivate, Verfahren zu ihrer Herstellung, diese enthaltende Arzneimittel und ihre Verwendung
US4652573A (en) Calcium antagonist N-hetero ester 1,4-dihydropyridines
KR960009427B1 (ko) 1,4-디히드로피리딘 유도체, 그의 약학적 조성물 및 그 제조방법
JPS60214778A (ja) Ν置換３，４−ジヒドロピリミジン誘導体ならびにその製造法および用途
JPH0641464B2 (ja) ジヒドロピリジン類
US4895846A (en) Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters incorporating arylpiperazinylalkyl moieties
US4500527A (en) Antihypertensive 4[(3-alkylamino-2-hydroxypropyl)-oxyiminomethyl phenyl]-1,4-dihydropyridines
JPS62281860A (ja) アルキレンアミノアルキレン　ヘテロ原子基を有するジヒドロ−３，５−ジカルボキシレ−ト
JP2640245B2 (ja) １，４−ジヒドロピリジン誘導体
JPS6352031B2 (de)
EP0220917B1 (de) Pharmazeutische 1,4-Dihydropyridinderivate, ihre Salze und Herstellung
HU190900B (en) Process for preparing dihydro-pyridine derivatives
NZ207716A (en) 3-(2-furoyl)-5-alkoxy-2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine derivatives and pharmaceutical compositions
JPS6321674B2 (de)
EP0253370A1 (de) 1,3,5-Trithian-Derivate
EP0265947A2 (de) Dihydropyridin-Derivate, Verfahren zu deren Herstellung, pharmazeutische Zusammensetzungen und Verwendung
JPS62174051A (ja) 薬用に有用なジヒドロピリジニルジカルボン酸アミド及びエステル、並びにその製法

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)